CredoScientia - Bibliothèque

Intratumoral CXCL13 CD160 CD8 T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer.

BACKGROUND: Stage IV gastric cancer is a highly heterogeneous and lethal tumor with few therapeutic strategies. The combination of programmed cell death protein 1 inhibitors and chemotherapy is curren…

Thérapies de Conversion

Wang, J., Liang, Y., Xue, A., Xiao, J., Zhao, X., Cao, S., Li, P., Dong, J., Li, Y., Xu, Z., & Yang, L. (2024). Intratumoral CXCL13 CD160 CD8 T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer.. J Immunother Cancer, 12(9). https://doi.org/10.1136/jitc-2024-009603

06/09/2024 Lire →

ASO Author Reflections: Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Digital Intelligence Liver Surgery Technologies in Patients with HCC After Conversion Therapy.

Thérapies de Conversion

Liu, H., Deng, H., Fang, C., Yang, J., & Xiang, N. (2024). ASO Author Reflections: Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Digital Intelligence Liver Surgery Technologies in Patients with HCC After Conversion Therapy.. Ann Surg Oncol, 31(9), 5655-5657. https://doi.org/10.1245/s10434-024-15612-2

01/09/2024 Lire →

A commentary on 'Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study'.

Thérapies de Conversion

Luo, J., Yang, Q., Ma, W., & Fan, H. (2024). A commentary on 'Comparison of survival benefit and safety between surgery following conversion therapy versus surgery alone in patients with surgically resectable hepatocellular carcinoma at CNLC IIb/IIIa stage: a propensity score matching study'.. Int J Surg, 110(9), 6045-6046. https://doi.org/10.1097/JS9.0000000000001789

01/09/2024 Lire →

Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Augmented Reality Navigation Plus ICG Fluorescence Imaging in Patients with HCC After Conversion Therapy.

Thérapies de Conversion

Liu, H., Deng, H., Hu, H., Wu, C., Huang, D., Fang, C., Yang, J., & Xiang, N. (2024). Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Augmented Reality Navigation Plus ICG Fluorescence Imaging in Patients with HCC After Conversion Therapy.. Ann Surg Oncol, 31(9), 5642-5644. https://doi.org/10.1245/s10434-024-15471-x

01/09/2024 Lire →

Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature.

BACKGROUND: The detection rates of early gastric cancer (GC) in China are approximately 20%; upon diagnosis, the majority of patients with GC are identified as having advanced stage disease, and in so…

Thérapies de Conversion

Zhou, J., Wang, J., Wang, W., Sun, L., Zhao, S., Sun, Q., & Wang, D. (2024). Pathological Complete Response Achieved with XELOX Chemotherapy, HIPEC, and Anti-PD-1 Immunotherapy in Stage IV Gastric Adenocarcinoma with Peritoneal Metastasis: A Case Report and Review of the Literature.. J Gastrointest Cancer, 55(3), 1441-1447. https://doi.org/10.1007/s12029-024-01056-0

01/09/2024 Lire →

Conversion Therapy to Transplant or Surgical Resection in Patients with Unresectable Hepatocellular Carcinoma Treated with Boosted Dose of Yttrium-90 Radiation Segmentectomy.

BACKGROUND/OBJECTIVES: The aim of this study was to assess the efficacy of boosted dose yttrium-90 radioembolization (TARE) as a modality for conversion therapy to transplant or surgical resection in …

Thérapies de Conversion

Son, S. Y., Geevarghese, R., Marinelli, B., Zhao, K., Covey, A., Maxwell, A., Wei, A. C., Jarnagin, W., D'Angelica, M., & Yarmohammadi, H. (2024). Conversion Therapy to Transplant or Surgical Resection in Patients with Unresectable Hepatocellular Carcinoma Treated with Boosted Dose of Yttrium-90 Radiation Segmentectomy.. Cancers (Basel), 16(17). https://doi.org/10.3390/cancers16173024

30/08/2024 Lire →

Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.

BACKGROUND: Local treatment may function synergistically with immunotherapy and targeted agents. This study aimed to assess the effectiveness and safety of transcatheter arterial chemoembolization (TA…

Thérapies de Conversion

Pang, B., Zuo, B., Huang, L., You, X., Liu, T., Hao, J., Yuan, C., Yang, C., Yee, L. a. u. . W., & Zhang, Y. (2024). Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.. Int Immunopharmacol, 137, 112492. https://doi.org/10.1016/j.intimp.2024.112492

20/08/2024 Lire →

Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

BACKGROUND: Systemic conversion therapy provides patients with initially unresectable hepatocellular carcinoma (HCC) the chance to salvage radical liver resection and superior survival outcomes, but t…

Thérapies de Conversion

Xu, H., Zhang, H., Li, B., Chen, K., & Wei, Y. (2024). Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.. BMC Cancer, 24(1), 1008. https://doi.org/10.1186/s12885-024-12772-y

14/08/2024 Lire →

Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody.

BACKGROUND: This study aimed to compare the survival outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) who underwent or did not unde…

Thérapies de Conversion

Wang, L., Feng, J. K., Lu, C. D., Wu, J. Y., Zhou, B., Wang, K., Wei, X. B., Liang, C., Zhou, H. K., Shi, J., Guo, W. X., Lau, W. Y., Yan, M. L., & Cheng, S. Q. (2024). Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody.. Oncologist, 29(8), e1041-e1050. https://doi.org/10.1093/oncolo/oyae032

05/08/2024 Lire →

A case of conversion therapy for hepatocellular carcinoma with bile-duct tumor thrombus.

Thérapies de Conversion

Wu, J. L., Peng, P., Hu, Z. M., & Sun, Q. (2024). A case of conversion therapy for hepatocellular carcinoma with bile-duct tumor thrombus.. Asian J Surg, 47(8), 3688-3689. https://doi.org/10.1016/j.asjsur.2024.04.039

01/08/2024 Lire →

Pathological complete remission (CR) in a patient with unresectable gastric cancer undergoing preoperative conversion therapy.

Thérapies de Conversion

Hu, R., Liu, C., & Li, D. (2024). Pathological complete remission (CR) in a patient with unresectable gastric cancer undergoing preoperative conversion therapy.. Asian J Surg, 47(8), 3534-3535. https://doi.org/10.1016/j.asjsur.2023.09.002

01/08/2024 Lire →

Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

AIM: The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although convers…

Thérapies de Conversion

Ishihara, N., Komatsu, S., Sofue, K., Ueshima, E., Yano, Y., Fujishima, Y., Ishida, J., Kido, M., Gon, H., Fukushima, K., Urade, T., Yanagimoto, H., Toyama, H., Ueda, Y., Kodama, Y., Murakami, T., & Fukumoto, T. (2024). Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.. Hepatol Res, 54(8), 773-780. https://doi.org/10.1111/hepr.14024

01/08/2024 Lire →